Omega-3 fatty acids are among the few supplements with randomized evidence for all-cause mortality reduction. Here is what the VITAL trial actually showed, who benefits most, and which products deliver the dose and form the research uses.
Of all the supplements discussed in longevity circles, omega-3 fatty acids have the largest randomized trial base and one of the most surprising research stories of the past decade. After years of conflicting meta-analyses — many of which pooled extremely low-dose trials with therapeutic-dose trials — the 25,871-participant VITAL trial published in the *New England Journal of Medicine* in 2019 provided the clearest signal yet: at 1 g/day of marine omega-3, the study found a 28% reduction in fatal myocardial infarction and statistically significant reductions in total MI, with a particularly strong signal in people who ate little fish at baseline.
This is not a niche finding. Cardiovascular disease remains the leading cause of death, and a 28% reduction in fatal MI from a supplement with an excellent safety profile and a cost of under $0.50/day represents one of the best risk-adjusted longevity investments available without a prescription.
The mechanism extends beyond the heart. EPA and DHA are the primary substrates for specialized pro-resolving mediators — resolvins, protectins, and maresins — which actively terminate inflammation. They are also essential for brain membrane structure, BDNF production, and synaptic plasticity. The omega-3 story is not just cardiovascular: it is a story about maintaining the anti-inflammatory and neuroprotective infrastructure that underpins healthspan.
Long-chain omega-3 fatty acids — eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) — are structurally and functionally distinct from alpha-linolenic acid (ALA), the short-chain omega-3 found in flaxseed, walnuts, and chia. The body converts ALA to EPA and DHA inefficiently (roughly 5–10% for EPA, less than 1% for DHA). Dietary or supplemental EPA and DHA are not interchangeable with ALA — they are the biologically active forms.
The practical implication: EPA and DHA have overlapping but distinct effects. Cardiovascular and inflammatory applications favor EPA; neurological and DHA-specific membrane maintenance favors DHA. Most longevity protocols benefit from both, making a balanced EPA+DHA supplement the default — with EPA-dominant products reserved for those with primarily cardiovascular or inflammatory goals.